** Shares of telehealth firm Hims & Hers Health HIMS.N fall 6.5% to $61.88 premarket
** Trump administration is planning to cover weight-loss drugs under Medicare and Medicaid, Washington Post reports
** Proposed plan would permit state Medicaid programs and Medicare Part D insurance plans to voluntarily cover GLP-1 drugs such as Novo Nordisk's NOVOb.CO Ozempic and Wegovy, as well as Lilly's Mounjaro and Zepbound for weight management, report says
** Proposed plan is expected to start in April 2026 for Medicaid and in January 2027 for Medicare plans, Washington Post reports, citing documents
** As of last close, stock up 173% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。